Posted by Michael Wonder on 20 May 2024
FDA approves first interchangeable biosimilars to Eylea to treat macular degeneration and other eye conditions
20 May 2024 - Today, FDA approved Yesafili (aflibercept-jbvf) and Opuviz (aflibercecpt-yszy) as the first interchangeable biosimilars to Eylea (aflibercept).
FDA’s approvals of Yesafili and Opuviz are based on a comprehensive review of scientific evidence demonstrating that each product is highly similar to Eylea, respectively, and that they have no clinically meaningful differences from Eylea.
